Severe asthma presents substantial clinical challenges due to persistent airway inflammation and marked heterogeneity in biologic treatment response. Emerging research highlights the gut lung axis asthma network as an essential driver of systemic immune responses and respiratory inflammation. In this context, investigators from the multicenter Precision Medicine Intervention in Severe Asthma (PRISM) study evaluated concurrent microbial signatures across multiple compartments. Their groundbreaking findings demonstrate that intestinal and respiratory microbial ecosystems provide complementary insights into dupilumab response trajectories.

The Emerging Role of the Gut Lung Axis Asthma Network

Biologic therapies targeting type 2 inflammation, such as dupilumab, have transformed the management of severe asthma. Dupilumab inhibits interleukin-4 and interleukin-13 signaling pathways, thereby dampening allergic inflammation and decreasing exacerbations. However, clinical response remains variable among treated individuals. Consequently, clinicians require objective biomarkers to predict therapeutic outcomes accurately. Historically, medical investigations focused predominantly on isolated pulmonary compartments to understand treatment failure. Recent discoveries demonstrate that mucosal surfaces maintain continuous immunological crosstalk. Intestinal microbes produce functional metabolites, such as short-chain fatty acids, that circulate systemically to regulate bone marrow hematopoiesis and distal airway tolerance. Conversely, systemic immune signals modulate mucosal integrity and microbial colonization patterns in both the lungs and the digestive tract. Therefore, investigating bidirectional microbial shifts offers an innovative roadmap to resolve treatment heterogeneity in clinical practice.

Multi-Compartment Profiling in the PRISM Study

To characterize these biological interactions, the PRISM prospective observational study evaluated 48 patients with severe asthma receiving dupilumab. The investigators analyzed microbiomes across three distinct compartments: stool bacteria, stool-derived extracellular vesicles, and exhaled breath condensate. Stool-derived extracellular vesicles represent crucial nanoscale mediators that carry microbial proteins and nucleic acids through systemic circulation to interact directly with host immune cells. Meanwhile, exhaled breath condensate captures the volatile and non-volatile biochemical signatures of the lower respiratory tract non-invasively. The researchers systematically evaluated microbial community composition, alpha diversity metrics, and predicted functional genetic pathways before and after biologic administration. Furthermore, they correlated these longitudinal microbial shifts with established clinical markers, including blood and sputum eosinophil levels. By comparing cellular and extracellular components concurrently, the study revealed intricate compartment-specific features previously overlooked by single-site analyses.

Airway Microbiome Signatures and Sputum Eosinophilia

The study demonstrated distinct taxonomic and predicted metabolic functional profiles between biological compartments. Notably, exhaled breath condensate samples exhibited substantial enrichment of the phylum Proteobacteria, particularly the genus Pseudomonas. Functional metagenomic profiling indicated that airway communities displayed higher abundances of genes related to bacterial two-component regulatory systems and secretion pathways. Importantly, baseline airway microbial alpha diversity correlated positively with baseline sputum eosinophil percentages. This direct relationship emphasizes that local respiratory microbial dysbiosis intimately mirrors localized airway eosinophilic inflammation. Pathobiont expansion within the bronchial tree may stimulate airway epithelial cells to release alarmins, including thymic stromal lymphopoietin and interleukin-33. These epithelial cytokines perpetuate downstream type 2 mucosal responses. Consequently, sampling exhaled breath condensate provides clinicians with a sensitive, non-invasive surrogate to evaluate localized bronchial inflammatory burdens.

Stool Microbial Dynamics and Systemic Inflammatory Markers

In contrast to local airway patterns, intestinal microbial communities mirrored systemic immunological fluctuations. The authors identified a significant time-dependent interaction between stool microbial richness and peripheral blood eosinophil counts during dupilumab therapy. Biologic blockade of interleukin-4 receptor alpha frequently causes transient peripheral eosinophilia by preventing tissue extravasation. Interestingly, fluctuations in stool bacterial richness closely paralleled these systemic eosinophil shifts over time. In addition, stool-derived extracellular vesicles revealed distinct immunological interfaces, demonstrating how bacterial nanovesicles access vascular channels to modulate systemic immunity. These findings confirm that intestinal microbial signatures reflect systemic inflammatory tone rather than localized bronchial pathology. Thus, analyzing fecal cellular and vesicular fractions provides critical context regarding how the host immune system responds systemically to cytokine blockade.

Taxonomic Predictors of Dupilumab Treatment Response

Most importantly, the PRISM investigators uncovered clear taxonomic differences between treatment responders and non-responders. Patients achieving optimal clinical responses displayed significantly lower abundances of Lachnospira in both stool bacteria and extracellular vesicles. Similarly, treatment responders exhibited reduced levels of potential pathobionts, specifically Escherichia-Shigella, within stool-derived extracellular vesicles. Conversely, responders demonstrated a significantly higher relative abundance of the beneficial Oscillospiraceae NK4A214 group across cellular and vesicular stool profiles. Members of the Oscillospiraceae family actively produce butyrate, a short-chain fatty acid known to enhance regulatory T-cell differentiation and suppress systemic inflammatory cascades. In contrast, pro-inflammatory taxa like Escherichia-Shigella trigger mucosal barrier disruption and endotoxemia. Therefore, a balanced gut ecosystem enriched with immunomodulatory commensals appears to foster favorable physiological conditions for biologic efficacy.

Clinical Implications for Precision Medicine in India

These findings present vital translational relevance for pulmonary and internal medicine specialists managing severe asthma in India. India faces an immense burden of severe obstructive airway disease, often complicated by unique environmental allergens, biomass exposure, and recurrent respiratory infections. Moreover, high dietary diversity and frequent over-the-counter antibiotic utilization across Indian populations significantly influence baseline gut and lung microbiomes. As expensive biologics like dupilumab gain broader adoption across tertiary healthcare centers in India, identifying reliable biomarkers of response becomes paramount for cost-effective therapy. Integrating stool and airway microbial profiling may eventually help Indian physicians stratify patients before initiating therapy. Furthermore, targeted adjunctive strategies, such as dietary fiber optimization or precision gut microbiota modulation, could potentially improve biologic responsiveness in patients with severe uncontrolled asthma.

How does the gut-lung axis modulate biologic therapy outcomes in asthma?

The gut-lung axis operates through bidirectional biochemical communication networks between intestinal microbes and pulmonary tissues. Intestinal bacteria produce bioactive metabolites, such as short-chain fatty acids, that enter systemic circulation. These microbial signals prime immune cell development within the bone marrow and regulate systemic inflammation. Consequently, a balanced gut microbiome establishes an optimal immunologic environment, enhancing therapeutic responsiveness to targeted biologics like dupilumab.

Which specific gut bacterial taxa differentiate dupilumab responders from non-responders?

According to the PRISM study, clinical responders to dupilumab exhibit significantly lower relative abundances of Lachnospira and Escherichia-Shigella in stool and stool-derived extracellular vesicles. Conversely, responders show a significantly higher abundance of the Oscillospiraceae NK4A214 group. These microbial differences suggest that butyrate-producing commensals favor positive clinical responses, whereas pathobionts promote persistent inflammation.

What role does exhaled breath condensate analysis play in evaluating airway dysbiosis?

Exhaled breath condensate collects non-volatile droplets from the lower respiratory tract, offering a completely non-invasive method to evaluate airway microbiota. In the PRISM study, exhaled condensate was enriched with Proteobacteria, including Pseudomonas. Furthermore, microbial diversity in condensate correlated directly with baseline sputum eosinophils, confirming that exhaled breath profiling mirrors localized bronchial inflammation reliably.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice or relied on for treatment decisions. Refer to the latest local and national guidelines for clinical practice.

References

Yie GE et al. Stool and Airway Microbiome Signatures Associated With Treatment Response to Dupilumab in Severe Asthma: Findings From the PRISM Study. Allergy. 2026 Sep 22. doi: 10.1111/all.70524. PMID: 42773061.

From Gut to Lung: The Microbiome-Directed Causal Mechanisms and Therapeutic Horizons in Asthma. Frontiers in Microbiology. 2026;17:1680521.

Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review. Current Allergy and Asthma Reports. 2025;25(4):112-124.